Bausch Health Companies Overview

  • Year Founded
  • 1959

Year Founded

  • Status
  • Public

  • Employees
  • 20,300

Employees

  • Stock Symbol
  • BHC

Stock Symbol

  • Investments
  • 69

  • Share Price
  • $8.24
  • (As of Friday Closing)

Bausch Health Companies General Information

Description

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Contact Information

Formerly Known As
Valeant Pharmaceuticals International, ICN Biomedicals, ICN Pharmaceuticals, Viratek, Valeant Pharmaceuticals, Icn Merger, Biovail Corp International
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 2150 Street Elzéar Boulevard West
  • Laval, Quebec H7L 4A8
  • Canada
+1 (800)
Primary Industry
Pharmaceuticals
Other Industries
Other Devices and Supplies
Surgical Devices
Stock Exchange
TSE
Corporate Office
  • 2150 Street Elzéar Boulevard West
  • Laval, Quebec H7L 4A8
  • Canada
+1 (800)

Bausch Health Companies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bausch Health Companies Stock Performance

As of 20-Nov-2026, Bausch Health Companies’s stock price is $8.24. Its current market cap is $3.08B with 374M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.24 $8.58 $4.33 - $9.04 $3.08B 374M 662K -$2.25

Bausch Health Companies Financials Summary

As of 30-Sep-2026, Bausch Health Companies has a trailing 12-month revenue of $11.1B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 22,134,489 23,566,501 23,425,005 26,164,223
Revenue 11,113,000 10,266,000 9,625,000 8,757,000
EBITDA 2,347,000 3,131,000 2,789,000 2,176,000
Net Income (841,000) 157,000 (46,000) (592,000)
Total Assets 25,484,000 26,366,000 26,523,000 27,350,000
Total Debt 20,715,000 20,851,000 21,616,000 22,388,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bausch Health Companies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bausch Health Companies‘s full profile, request access.

Request a free trial

Bausch Health Companies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a
Pharmaceuticals
Laval, Canada
20,300 As of 2025

Ahmedabad, India
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bausch Health Companies Competitors (3)

One of Bausch Health Companies’s 3 competitors is Zydus Lifesciences, a Corporation company based in Ahmedabad, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zydus Lifesciences Corporation Ahmedabad, India
Evonile Pharma Private Equity-Backed Mumbai, India
Novartis Corporation Basel, Switzerland
You’re viewing 3 of 3 competitors. Get the full list »

Bausch Health Companies Patents

Bausch Health Companies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025134072-A1 Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod Inactive 21-Dec-2023
US-20260240825-A1 Topical compositions Pending 11-Apr-2023
WO-2024213629-A1 Topical compositions Inactive 11-Apr-2023
US-20260224591-A1 Use of a fixed combination of halobetasol propionate and tazarotene to treat conditions mediated by interleukin-17a Pending 31-Dec-2022
WO-2024141639-A1 Use of a fixed combination of halobetasol propionate and tazarotene to treat conditions mediated by interleukin-17a Inactive 31-Dec-2022 A61K45/06
To view Bausch Health Companies’s complete patent history, request access »

Bausch Health Companies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bausch Health Companies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bausch Health Companies‘s full profile, request access.

Request a free trial

Bausch Health Companies Investments & Acquisitions (69)

Bausch Health Companies’s most recent deal was a Merger/Acquisition with MID Labs. The deal was made on 09-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
MID Labs 09-Oct-2026 Merger/Acquisition Surgical Devices
Vision Beauty 01-Dec-2025 Merger/Acquisition Distributors/Wholesale
Durect 11-Sep-2025 Merger/Acquisition Drug Discovery
Synergy Pharmaceuticals 06-Mar-2019 Merger/Acquisition Other Healthcare Services
Synergy Pharmaceuticals 31-Dec-2015 Merger/Acquisition Other Healthcare Services
You’re viewing 5 of 69 investments and acquisitions. Get the full list »

Bausch Health Companies ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

27.72 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Bausch Health Companies’s complete esg history, request access »

Bausch Health Companies Exits (17)

Bausch Health Companies’s most recent exit was on 01-Oct-2015 from Addyi. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Addyi 01-Oct-2015 Completed
Amoun Pharmaceutical Company 17-Jul-2015 Completed
Paragon Vision Sciences 18-May-2015 Completed
Dendreon 23-Feb-2015 Completed
Allergan (Acquired 2015) 20-Nov-2014 Secondary Transaction - Private Completed
You’re viewing 5 of 17 exits. Get the full list »

Bausch Health Companies Affiliates

Subsidiaries (8)

Name Industry Location Year Founded
Biovail Americas Corp Bridgewater, NJ 2007
Onpharma Carson City, NV 2005
Biovail Pharmaceuticals Bridgewater, NJ 1997
Solta Medical Hayward, CA 1995
Biovail Technologies Aliso Viejo, CA 1988
You’re viewing 5 of 8 affiliates. Get the full list.  »

Bausch Health Companies FAQs

  • When was Bausch Health Companies founded?

    Bausch Health Companies was founded in 1959.

  • Where is Bausch Health Companies headquartered?

    Bausch Health Companies is headquartered in Laval, Canada.

  • What is the size of Bausch Health Companies?

    Bausch Health Companies has 20,300 total employees.

  • What industry is Bausch Health Companies in?

    Bausch Health Companies’s primary industry is Pharmaceuticals.

  • Is Bausch Health Companies a private or public company?

    Bausch Health Companies is a Public company.

  • What is Bausch Health Companies’s stock symbol?

    The ticker symbol for Bausch Health Companies is BHC.

  • What is the current stock price of Bausch Health Companies?

    As of 20-Nov-2026 the stock price of Bausch Health Companies is $8.24.

  • What is the current market cap of Bausch Health Companies?

    The current market capitalization of Bausch Health Companies is $3.08B.

  • What is Bausch Health Companies’s current revenue?

    The trailing twelve month revenue for Bausch Health Companies is $11.1B.

  • Who are Bausch Health Companies’s competitors?

    Zydus Lifesciences, Evonile Pharma, and Novartis are competitors of Bausch Health Companies.

  • What is Bausch Health Companies’s annual earnings per share (EPS)?

    Bausch Health Companies’s EPS for 12 months was -$2.25.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process